Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05991323 · ClinicalTrials.gov registry record

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

A clinical trial of Prurigo Nodularis, sponsored by Sanofi.

Active
Registry status
100
Enrollment target
20
Study locations

NCT05991323 is a study of Prurigo Nodularis that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 100 participants, below the 222-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05991323, a study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Sanofi.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
20
Study locations

Study Summary

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Conditions Studied

Prurigo Nodularis

Interventions

  • DRUG Dupilumab

Study Locations (20)

California

  • Center for Dermatology Clinical Research- Site Number : 8400002 - Fremont
  • Halcyon Dermatology- Site Number : 8400023 - Laguna Hills
  • Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015 - Rancho Santa Margarita
  • Golden State Dermatology- Site Number : 8400014 - Walnut Creek

Michigan

  • Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007 - Auburn Hills
  • Derm Institute of Western Michigan- Site Number : 8400034 - Caledonia
  • Dermatology Associates Western Michigan- Site Number : 8400033 - Grand Rapids

Arizona

  • Medical Dermatology Specialists Site Number : 8400005 - Phoenix
  • Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024 - Phoenix

Florida

  • Total Vein And Skin, LLC- Site Number : 8400019 - Boynton Beach
  • GSI Clinical Research- Site Number : 8400017 - Margate

Nevada

  • Vivida Dermatology - Flamingo- Site Number : 8400013 - Las Vegas
  • Las Vegas Dermatology- Site Number : 8400027 - Las Vegas

Georgia

  • Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025 - Columbus

Indiana

  • Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003 - Indianapolis

Missouri

  • U.S. Dermatology Partners Lee's Summit- Site Number : 8400016 - Lee's Summit

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-12-12
Est. Completion 2026-09-22

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05991323

The ClinicalTrials.gov registry entry for NCT05991323 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (55% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.

NCT05991323 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Arizona.

Frequently Asked Questions

What is clinical trial NCT05991323 about?

NCT05991323 is a clinical study titled "Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study". This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the ...

What is the current status of trial NCT05991323?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-12-12. Estimated completion is 2026-09-22.

What conditions does trial NCT05991323 study?

This clinical trial studies the following conditions: Prurigo Nodularis.

What interventions are being tested in trial NCT05991323?

The interventions under investigation include: Dupilumab (DRUG).

Who is sponsoring clinical trial NCT05991323?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05991323 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prurigo Nodularis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prurigo Nodularis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.